Published in Gene Therapy Weekly, August 22nd, 2002
Financial terms were not disclosed.
"We are utilizing microarrays for the functional profiling of proteins by identifying key genes and proteins directly related to the clinical endpoint and will be using a 'chemical library chip' to find small molecules interacting with those key proteins," said Daniel Zurr, CEO of Quark Biotech.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly